Innovent Biologics, Inc. (IVBXF)
OTCMKTS
· Delayed Price · Currency is USD
10.50
+0.26 (2.54%)
Jul 3, 2025, 9:30 AM EDT
Innovent Biologics Revenue
In the year 2024, Innovent Biologics had annual revenue of 9.42B CNY with 51.82% growth. Innovent Biologics had revenue of 5.47B in the half year ending December 31, 2024, with 136.09% growth.
Revenue
9.42B CNY
Revenue Growth
+51.82%
P/S Ratio
14.54
Revenue / Employee
1.66M CNY
Employees
5,659
Market Cap
18.77B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Elite Pharmaceuticals | 84.04M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 215.62M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
Innovent Biologics News
- 6 days ago - Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide - Seeking Alpha
- 7 days ago - Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms - PRNewsWire
- 9 days ago - Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management - PRNewsWire
- 12 days ago - Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions - PRNewsWire
- 13 days ago - Neutral On Innovent Biologics: Hard To Justify Its Premium - Seeking Alpha
- 15 days ago - Multiple Research Results from Innovent's General Biomedicine Pipeline to be Showcased at the ADA 85th Scientific Sessions - PRNewsWire
- 21 days ago - Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China - PRNewsWire
- 24 days ago - Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions - PRNewsWire